Unraveling the Neuroprotective Mechanisms of Curcumin in Alzheimer's Disease: Insights from Suppl. Fig. 4

Feb 18, 2025

10 likes | 98 Views

This study delves into the neuroprotective effects of curcumin in Alzheimer's disease, providing valuable insights from Suppl. Fig. 4. Discover the potential therapeutic benefits and mechanisms of action through in-depth analysis.

Share Presentation

Embed Code

talen

Download Presentation

Unraveling the Neuroprotective Mechanisms of Curcumin in Alzheimer's Disease: Insights from Suppl. Fig. 4

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

Suppl. Fig. 4

(Suppl. Fig . 1)

(Suppl. Fig . 1). primary HCC samples & non-cancerous tissues, from 61 patients (Table 1). RMA normalization Limma (p values) pFDR (q values). Bioconductor packages. Training cohort I (Fig. 1A-B; GSE45267 ). 449. Training cohort II (Fig. 1C; GSE45434 ). 247. 10500. Young HCC

229 views • 1 slides

Suppl. Fig. S1

Suppl. Fig. S1.

206 views • 9 slides

Suppl. Fig . 1

137 views • 1 slides

Suppl. Fig. 1

Suppl. Fig. 1. Day 14. Day 42. Day 7. Day 28. 4. 4. 5. 6. 4. 11. 5. 6. 4. 11. 5. 6. 7. 8. 9. 10. 11. 5. 6. 7. 8. 9. 10. 11. 7. 8. 9. 10. 7. 8. 9. 10. 13. 13. 13. 13. 13. 12. 13. 12. 13. 12. 13. 12. 12. 13. 12. 13. 13. 12. 13. 13. 12. 12.

100 views • 1 slides

Suppl Fig. 1

B/Uganda/MUWRP-064/2009. B/Uganda/MUWRP-068/2009. B/Uganda/MUWRP-055/2009. B/Uganda/MUWRP-081/2009. B/Uganda/MUWRP-073/2009. B/Uganda/MUWRP-054/2009. 87. B/Uganda/MUWRP-063/2009. 100. B/Uganda/MUWRP-077/2009. B/Brisbane/60/2008. B/Fujian- Gulou /1272/2008. B/Florida/4/2006.

187 views • 1 slides

Suppl. Fig.1

No PI. Bax. Suppl. Fig.1. 200. Control. 0%. Ku80. 43.75%. Matsuyama. b. Control. c. 200. Counts. Ku80. 8.78%. Ku70wt. 80. b -Tubulin. M1. Counts. 0. Control. 0.5 m g. 1.0 m g. 2.0 m g. 0. 1. 2. 3. 4. 10. 10. 10. 10. 10. 60. FL2-H. M1. Ku70. 0. 0. 1.

142 views • 4 slides

Suppl. Fig. 2

Suppl. Fig. 2.

148 views • 1 slides

Suppl. Fig. 1

Suppl. Fig. 1. Suppl. Fig. 1 Characterisation of three independent iAGP-pea lines. Embryos from independent lines iAGP-1, 2 and 3 were analysed for AGP small subunit-mRNA (A), AGP-activity (B), starch (C), vicilin mRNA (D) and legumin-mRNA (E). Suppl. Fig. 2.

174 views • 3 slides

Suppl. Fig. 2

Suppl. Fig. 2. A. Cntrl. FasL 25ng/ml. B. 0.5 FasL +zVAD. 25 FasL + α -Fas. 25 FasL+ zVAD. 0.5 FasL +zVAD. 25 FasL+ zVAD. 25 FasL +zVAD. 0.5 FasL. 25 FasL. 0.5 FasL. 25 FasL. 5 FasL. α -Fas. zVAD. HuT78. Cntrl. Cntrl. zVAD. 0.5 FasL. Cntrl. 25 FasL. zVAD. Cntrl.

155 views • 1 slides

Suppl. Fig. 2

4. 4. 3. 3. sugar concentration log ng/µl serum or ng/µg. sugar concentration log ng/µl serum or ng/µg. 2. 2. 1. 1. 0. 0. Suppl. Fig. 2. A. B. C. i.p. oral L-arabinose. oral L-rhamnose. 4. Serum. Serum. L-arabinose. Cecum. Cecum. L-rhamnose. SI. SI. 3. LI. LI.

140 views • 1 slides

Suppl. Fig.2

Zou et al. Suppl. Fig.2. A. B. ECM Gel. Cell Culture plate. HA- b -Arr1 1-180. HA- b -Arr1 1-240. HA- b -Arr1 1-320. HA- b -Arr1 181-418. HA- b -Arr1 214-418. HA- b -Arr1 318-418. b -gal. HA- b -Arr1. C. MMP9 Activity. Angiogenesis. +. +. HA- b -Arr1. -. -.

116 views • 1 slides

Suppl. Fig S1

1x10 12 (1x10 4 / Hepatocyte). 2x10 11 (2x10 3 / Hepatocyte). 5x10 10 (5x10 2 / Hepatocyte). 2x10 10 (2x10 2 / Hepatocyte). U6 --. U6 --. AH --. S25. U6 --. U6 --. AH --. S25. H1 --. FATP. U6 --. U6 --. H19. p53 S25 H25. H19 S19 L29. p53 S25 H25. H19 S19 L29.

100 views • 1 slides

Suppl. Fig. 1

Suppl. Fig. 1. GL-261 NS. SMA-560 NS. Suppl. Fig. 2. RAD. GL-261. SMA-560. Cil. Merge. Merge. NHS-Biotin. NHS-Biotin. Nucleus. Nucleus. Suppl. Fig. 3. A. B. Suppl. Fig. 4. SMA-560 SC. RAD. Cil. Stauro. Suppl. Fig. 5. GL-261 NS. SMA-560 NS. SMA-560 NS. GL-261 NS.

186 views • 6 slides

Suppl Fig. S1

Suppl Fig. S1. 3 H-thymidine incorporation (cpm). *. *. 100 μ M. Kynurenine concentration. 100 µM. 10 µM. 0 µM. 3HK. 0 µM. 100 µM. 10 µM. 3HAA. Suppl Fig. S2. 25 µM. 0 µM. 50 µM. 100 µM. 3HK. A. 25 µM. 50 µM. 100 µM. 0 µM. 3HAA. B. Suppl Fig. S3. Kyn. 3HK.

175 views • 4 slides

Suppl. Fig. 3

Suppl. Fig. 3. # 2. # 1. A. # 1. B. 42%. AD. # 2. 44%. AD/FasL. # 3. 39%. AD/FasL/ a -Fas. Analysis of BM-MSC adipogenesis.

105 views • 1 slides

Suppl. Fig. 1A

Suppl. Fig. 1A. Suppl. Fig. 1B. Suppl. Fig.1C.

138 views • 2 slides

Suppl. Fig. 1

Suppl. Fig. 1. A. B. P BAD. P rha. 4. 4. 3. 3. Bioluminescence x 10 10 (p/s/cm 2 /sr). Bioluminescence x 10 11 (p/s/cm 2 /sr). 2. 2. 1. 1. 0. 0. 0. 10. 20. 30. 40. 50. 0. 10. 20. 30. 40. 50. Time (h). Time (h).

119 views • 1 slides

Suppl. Fig. 1

Suppl. Fig. 1. A. B. C. 1600. Pre-treatment. vehicle. 10000. vehicle. 24 hr. 1400. 800. Dulanermin 60 mg/kg. Dulanermin 60 mg/kg. 48 hr. 1200. 8000. 600. 1000. 6000. Luminescence (RLU). M30 antigen (U/L). Mean tumor vol (mm 3 ). 800. 400. 600. 4000. 400. 200. 2000.

153 views • 2 slides

Suppl. Fig . S2

Supplementary Figure S1-S2. Suppl. Fig . S2. Suppl. Fig . S1. Cd. Control. Fig. S2B. Fig. S2A. MRP1. MK. Prob. MK. Prob. Cd - + - + - +. Cd - + - + - +. MRP1. p-Ser GSK3 αβ. Procaspase-3. p-Tyr GSK3 αβ. Cleaved caspase-3. Hoechst. GSK3 αβ.

187 views • 4 slides

Suppl. Fig.1

Flag-TDP-43WT. Flag-TDP-12xQ/N. -. -. TET. +. +. 80. 58. 46. 30. a -Flag. a -Tub. Suppl. Fig.1. Flag-TDP-43WT (+ TET). Flag-TDP-12xQ/N (+ TET). a - TDP-43. a -HSP70. MERGE ( a - TDP-43/ a -HSP70. MERGE ( a - TDP-43/ a - Flag /TOPRO-3. Suppl.Fig. 2. Flag- TDP-12xQ/N.

214 views • 6 slides

Suppl. fig. 6

Suppl. fig. 6. A. vehicle. cisplatin. p53. p53. B. C. DAPI. DAPI.

101 views • 1 slides

Suppl. Fig. S3

Suppl. Fig. S3.

89 views • 1 slides

More Related